170 related articles for article (PubMed ID: 28430399)
1. Targeting Conformational Activation of CDK2 Kinase.
Pellerano M; Tcherniuk S; Perals C; Ngoc Van TN; Garcin E; Mahuteau-Betzer F; Teulade-Fichou MP; Morris MC
Biotechnol J; 2017 Aug; 12(8):. PubMed ID: 28430399
[TBL] [Abstract][Full Text] [Related]
2. Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors.
Nandha Premnath P; Craig S; McInnes C
J Vis Exp; 2015 Oct; (105):e52441. PubMed ID: 26554946
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.
Rastelli G; Anighoro A; Chripkova M; Carrassa L; Broggini M
Cell Cycle; 2014; 13(14):2296-305. PubMed ID: 24911186
[TBL] [Abstract][Full Text] [Related]
4. Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
Prével C; Kurzawa L; Van TN; Morris MC
Eur J Med Chem; 2014 Dec; 88():74-88. PubMed ID: 25314935
[TBL] [Abstract][Full Text] [Related]
5. Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.
Premnath PN; Craig SN; Liu S; McInnes C
Bioorg Med Chem Lett; 2016 Aug; 26(15):3754-60. PubMed ID: 27297568
[TBL] [Abstract][Full Text] [Related]
6. Probing an Allosteric Pocket of CDK2 with Small Molecules.
Christodoulou MS; Caporuscio F; Restelli V; Carlino L; Cannazza G; Costanzi E; Citti C; Lo Presti L; Pisani P; Battistutta R; Broggini M; Passarella D; Rastelli G
ChemMedChem; 2017 Jan; 12(1):33-41. PubMed ID: 27860401
[TBL] [Abstract][Full Text] [Related]
7. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
9. Conformational Equilibrium of CDK/Cyclin Complexes by Molecular Dynamics with Excited Normal Modes.
Floquet N; Costa MG; Batista PR; Renault P; Bisch PM; Raussin F; Martinez J; Morris MC; Perahia D
Biophys J; 2015 Sep; 109(6):1179-89. PubMed ID: 26255588
[TBL] [Abstract][Full Text] [Related]
10. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
11. Network-based modelling and percolation analysis of conformational dynamics and activation in the CDK2 and CDK4 proteins: dynamic and energetic polarization of the kinase lobes may determine divergence of the regulatory mechanisms.
Verkhivker GM
Mol Biosyst; 2017 Oct; 13(11):2235-2253. PubMed ID: 28926061
[TBL] [Abstract][Full Text] [Related]
12. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
13. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.
Deng Y; Shipps GW; Zhao L; Siddiqui MA; Popovici-Muller J; Curran PJ; Duca JS; Hruza AW; Fischmann TO; Madison VS; Zhang R; McNemar CW; Mayhood TW; Syto R; Annis A; Kirschmeier P; Lees EM; Parry DA; Windsor WT
Bioorg Med Chem Lett; 2014 Jan; 24(1):199-203. PubMed ID: 24332088
[TBL] [Abstract][Full Text] [Related]
14. Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice.
Faber EB; Wang N; John K; Sun L; Wong HL; Burban D; Francis R; Tian D; Hong KH; Yang A; Wang L; Elsaid M; Khalid H; Levinson NM; Schönbrunn E; Hawkinson JE; Georg GI
J Med Chem; 2023 Feb; 66(3):1928-1940. PubMed ID: 36701569
[TBL] [Abstract][Full Text] [Related]
15. Structural and binding studies of cyclin-dependent kinase 2 with NU6140 inhibitor.
Talapati SR; Goyal M; Nataraj V; Pothuganti M; R SM; Gore S; Ramachandra M; Antony T; More SS; Rao NK
Chem Biol Drug Des; 2021 Nov; 98(5):857-868. PubMed ID: 34423559
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
17. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.
Li Y; Zhang J; Gao W; Zhang L; Pan Y; Zhang S; Wang Y
Int J Mol Sci; 2015 Apr; 16(5):9314-40. PubMed ID: 25918937
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-Dependent Kinase (CDK) Inhibitors: Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines.
Coxon CR; Anscombe E; Harnor SJ; Martin MP; Carbain B; Golding BT; Hardcastle IR; Harlow LK; Korolchuk S; Matheson CJ; Newell DR; Noble ME; Sivaprakasam M; Tudhope SJ; Turner DM; Wang LZ; Wedge SR; Wong C; Griffin RJ; Endicott JA; Cano C
J Med Chem; 2017 Mar; 60(5):1746-1767. PubMed ID: 28005359
[TBL] [Abstract][Full Text] [Related]
19. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
20. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
